Shenzhen - Delayed Quote CNY

Daan Gene Co., Ltd. (002030.SZ)

Compare
6.21 -0.14 (-2.20%)
At close: 3:04 PM GMT+8
Loading Chart for 002030.SZ
DELL
  • Previous Close 6.35
  • Open 6.50
  • Bid 6.20 x --
  • Ask 6.21 x --
  • Day's Range 6.20 - 6.40
  • 52 Week Range 4.71 - 11.00
  • Volume 22,379,848
  • Avg. Volume 34,209,107
  • Market Cap (intraday) 8.715B
  • Beta (5Y Monthly) 0.58
  • PE Ratio (TTM) --
  • EPS (TTM) -0.53
  • Earnings Date --
  • Forward Dividend & Yield 0.02 (0.24%)
  • Ex-Dividend Date Jun 14, 2024
  • 1y Target Est --

Daan Gene Co., Ltd. researches and develops, manufactures, and sells clinical test reagents, instruments, and supporting consumables. The company offers fluorescence quantitative PCR products, enzyme-linked immunoassay products, instrument products, and scientific research service products. It also provides medical examination, and health consultation and management services, such as genetic susceptibility gene testing, tumor marker testing, cervical cancer screening, routine physical examination, and other health services. The company was formerly known as Da An Gene Co., Ltd. of Sun Yat-Sen University. The company was founded in 1988 and is headquartered in Guangzhou, the People's Republic of China.

www.daangene.com

1,968

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002030.SZ

View More

Performance Overview: 002030.SZ

Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

002030.SZ
35.68%
SSE Composite Index
11.96%

1-Year Return

002030.SZ
36.79%
SSE Composite Index
8.99%

3-Year Return

002030.SZ
59.56%
SSE Composite Index
5.89%

5-Year Return

002030.SZ
29.81%
SSE Composite Index
14.46%

Compare To: 002030.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002030.SZ

View More

Valuation Measures

Annual
As of 11/14/2024
  • Market Cap

    8.91B

  • Enterprise Value

    8.15B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    9.58

  • Price/Book (mrq)

    1.07

  • Enterprise Value/Revenue

    8.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -80.75%

  • Return on Assets (ttm)

    -4.26%

  • Return on Equity (ttm)

    -8.60%

  • Revenue (ttm)

    929.61M

  • Net Income Avi to Common (ttm)

    -750.65M

  • Diluted EPS (ttm)

    -0.53

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    934.51M

  • Total Debt/Equity (mrq)

    2.00%

  • Levered Free Cash Flow (ttm)

    -971.22M

Research Analysis: 002030.SZ

View More

Company Insights: 002030.SZ

Research Reports: 002030.SZ

View More

People Also Watch